SCHEMBL320822

SCHEMBL320822

C=CCOn1c(=O)[nH]c2ccc(C(=O)c3c(C)c(OC)c4ccccn34)cc2c1=O

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.37
MAPT P10636 7/20 0.37
HTT P42858 3/20 0.35
LMNA P02545 4/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
KMT2A Q03164 4/20 0.34
MEN1 O00255 2/20 0.34
MAPK1 P28482 2/20 0.34
KDM4E B2RXH2 2/20 0.34
HBB P68871 1/20 0.34
HSD17B10 Q99714 1/20 0.34
GAA P10253 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
NPC1 O15118 2/20 0.33
ATM Q13315 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12505752 0.88 CA12 (0.39) ALDH1A1MAPTHTTLMNASMN1; SMN2
SCHEMBL320577 0.84 MAPT (0.34) ALDH1A1MAPTHTTLMNASMN1; SMN2
SCHEMBL14916577 0.83 BRD4 (0.40) ALDH1A1MAPTHTTLMNASMN1; SMN2
SCHEMBL321863 0.83 CA12 (0.41) ALDH1A1MAPTHTTLMNASMN1; SMN2
SCHEMBL321471 0.83 ALDH1A1 (0.39) ALDH1A1MAPTHTTLMNASMN1; SMN2
SCHEMBL14917190 0.81 NPC1 (0.40) ALDH1A1MAPTHTTSMN1; SMN2KMT2A
SCHEMBL14916426 0.81 MAPT (0.39) ALDH1A1MAPTHTTLMNASMN1; SMN2
SCHEMBL31161039 0.79 SMN1; SMN2 (0.36) ALDH1A1MAPTHTTLMNASMN1; SMN2
SCHEMBL17004133 0.79 HTT (0.37) ALDH1A1MAPTHTTLMNASMN1; SMN2
SCHEMBL14916185 0.77 HTT (0.39) ALDH1A1MAPTHTTLMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590975-B1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2015-08-19 EP disclosed
US-8859544-B2 Indolizine derivatives, process for the preparation thereof and therapeutic use thereof SANOFI (FR) 2014-10-14 US disclosed
EP-2590975-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-15 EP disclosed
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-09 US disclosed
WO-2012004731-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CCNY, INMT, IDO1 ALDH1A1 3536/4885MAPT 961/4885HTT 1454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.